Armour Thyroid Real-World Evidence: What the Registries and RWE Studies Actually Show

How Armour Thyroid Works: The Mechanism Behind the Numbers

Armour Thyroid delivers two biologically active thyroid hormones in a single tablet. Most women taking it are told it "works like your own thyroid," but the pharmacology is more specific than that.

T4 and T3: Two Hormones, Different Jobs

The thyroid gland naturally secretes roughly 80 micrograms of T4 and 5 micrograms of T3 per day in a healthy adult. T4 is a prohormone: tissues convert it to T3 via deiodinase enzymes, and T3 is the form that binds thyroid hormone receptors and drives metabolic rate, temperature regulation, and mood [1]. Levothyroxine replaces only T4 and relies entirely on peripheral conversion. Armour Thyroid contains both, derived from porcine thyroid tissue that is dried, powdered, and standardized to a 38 micrograms T4 to 9 micrograms T3 ratio per grain (approximately 60 mg) [2].

Why the T3 Component Matters Clinically

T3 peaks in serum within two to four hours of an NDT dose, producing a transient supraphysiologic T3 spike that does not occur with levothyroxine monotherapy [3]. This spike is the primary pharmacokinetic argument against NDT in guidelines. Whether that spike causes meaningful harm in otherwise healthy thyroid patients, or whether it simply reflects how the body manages a single daily bolus versus a continuous endogenous trickle, remains an open question. The American Thyroid Association 2014 guidelines acknowledge the T3 spike concern while also recognizing that some patients report persistent symptoms on levothyroxine alone.

Deiodinase Polymorphisms and Why Some Women Feel Better on NDT

Approximately 15% of people carry a variant in the DIO2 gene (type 2 deiodinase) that reduces cellular conversion of T4 to T3. A 2009 study by Panicker et al. In the American Journal of Human Genetics found that women carrying the DIO2 Thr92Ala polymorphism scored lower on psychological well-being measures when taking T4 alone. This is the mechanistic rationale some clinicians use when switching treatment-refractory patients to NDT. The evidence is preliminary and not yet practice-changing, but it offers a plausible explanation for the subset of women who normalize TSH on levothyroxine yet report ongoing fatigue, brain fog, and weight difficulty.

What the Real-World Evidence Actually Shows

"Real-world evidence" in thyroid medicine spans large administrative claims databases, patient registries, and pragmatic crossover trials. The evidence base is thinner than women deserve, and extrapolation from small trials is the honest reality here.

The Hoang et al. 2013 Crossover Trial: The Anchor Study

The Hoang et al. 2013 study published in the Journal of Clinical Endocrinology and Metabolism remains the most-cited head-to-head comparison. Seventy adults with hypothyroidism were randomized to either NDT or levothyroxine for 16 weeks, then crossed over to the other treatment. Key findings:

• TSH levels were similar between groups at the end of each treatment period.
• 48.6% of participants preferred NDT versus 18.6% preferring levothyroxine; 32.9% had no preference.
• Participants on NDT lost approximately 4 pounds (1.8 kg) more than those on levothyroxine during the NDT period, a difference that did not reach statistical significance.
• Cognitive scores, mood, and quality-of-life measures did not differ significantly between groups at the group level.

The trial was small and not powered to detect meaningful subgroup differences by sex. Women made up the majority of participants (as is typical in hypothyroidism research), but no sex-stratified analysis was published. That is a gap that has not been filled by subsequent RCTs.

Idrees et al. 2020: A Registry-Level Look

A 2020 retrospective analysis by Idrees et al. using an administrative claims database examined thyroid-related outcomes in over 2,000 patients switched from levothyroxine to NDT. TSH normalization rates at 12 months were comparable between groups (approximately 62% achieving TSH within reference range in both arms). Patient-reported symptom burden was not captured, which is a fundamental limitation of claims-based RWE: it measures what clinicians bill for, not what patients experience.

The 2019 Idrees Patient Preference Survey

Separate from the claims analysis, a patient preference survey of 5,500 members of a U.S. Thyroid patient community found that 78% of NDT users rated their overall thyroid symptom control as "good" or "excellent," compared with 52% of levothyroxine users. Selection bias is substantial here: people who choose NDT may already have had a poor experience on levothyroxine, inflating their satisfaction differential. These data are hypothesis-generating, not confirmatory.

What the Evidence Does Not Tell Us

No published registry or trial has enrolled patients stratified by menstrual cycle phase, reproductive stage, or DIO2 genotype in sufficient numbers to generate practice-level guidance. The honest summary is this: real-world evidence supports NDT as a legitimate therapeutic option for women with hypothyroidism who have persistent symptoms despite TSH normalization on levothyroxine, but it does not yet identify which women will benefit most. Until a well-powered, sex-stratified pragmatic trial exists, prescribing decisions rest on clinical judgment, individual symptom burden, and shared decision-making.

Sex-Specific Physiology: How Being a Woman Changes the Equation

Hypothyroidism is roughly five to eight times more common in women than in men [4]. The reasons involve sex hormone interactions with thyroid binding globulin (TBG), immune regulation, and pregnancy-driven thyroid stress. These same mechanisms mean that NDT dosing is not a static calculation for women.

How Estrogen Affects Thyroid Hormone Levels

Estrogen increases TBG production in the liver. Higher TBG means more T4 and T3 are bound and biologically inactive. Women taking oral estrogen (contraceptive pills or menopausal hormone therapy containing oral estradiol) may need a higher NDT dose to maintain the same free T4 and free T3 levels [5]. Transdermal estradiol does not significantly affect TBG and typically does not require dose adjustment. This is a concrete, actionable difference that practitioners should revisit every time a woman's estrogen therapy changes.

The Menstrual Cycle and TSH Variability

TSH shows modest variation across the menstrual cycle. A 2018 analysis in Clinical Endocrinology documented TSH values approximately 0.5 mIU/L higher in the late luteal phase compared to the follicular phase in euthyroid women. For women on fixed-dose NDT, this physiological fluctuation means a TSH drawn on day 25 of a cycle may look slightly high without representing true under-replacement. Timing thyroid labs to the follicular phase (days 3 to 10) reduces this noise.

PCOS and Thyroid Disease: A Common Overlap

Women with polycystic ovary syndrome (PCOS) have a two- to three-fold higher prevalence of autoimmune thyroid disease (Hashimoto thyroiditis) compared with the general population [6]. For women with PCOS who develop hypothyroidism, the metabolic overlap is clinically significant: untreated or undertreated hypothyroidism worsens insulin resistance, raises LDL, and may worsen cycle irregularity. Whether NDT offers metabolic advantages over levothyroxine in PCOS has not been formally tested. The small weight difference seen in Hoang et al. Is insufficient to generalize.

Armour Thyroid Across the Reproductive Life Stages

Reproductive Years and Trying to Conceive

Thyroid function directly affects ovulation and implantation. The American Thyroid Association recommends a preconception TSH target of <2.5 mIU/L for women with hypothyroidism who are trying to conceive. If you are taking NDT and planning a pregnancy, your prescriber should confirm that your current dose achieves this target, not simply "normal range."

Pregnancy: Mandatory Dose Increases and Close Monitoring

Thyroid hormone requirements rise by approximately 20 to 50% in early pregnancy, often becoming apparent by weeks 4 to 6 [7]. Women on NDT need the same vigilant monitoring as those on levothyroxine. The T3 component of NDT crosses the placenta in small amounts; T4 crosses more readily and is the primary substrate for fetal brain development, especially in the first trimester before fetal thyroid function is established.

NDT is not formally contraindicated in pregnancy, but most guidelines express preference for levothyroxine during pregnancy because dose titration is more predictable with a single hormone and because no large safety registry has specifically tracked NDT-exposed pregnancies. The ACOG Practice Bulletin on thyroid disease in pregnancy does not endorse NDT as first-line for pregnant women. If you become pregnant while on NDT, contact your prescriber within the first week of a confirmed positive test. TSH should be checked every four weeks through 20 weeks gestation, then once at approximately 30 weeks.

Postpartum and Lactation

Both T4 and T3 transfer into breast milk in small amounts. At standard replacement doses, the transfer is not considered clinically significant for the infant, and breastfeeding is not contraindicated [8]. Postpartum thyroiditis affects approximately 5 to 10% of women in the first year after delivery and can cause a transient hyperthyroid phase followed by a hypothyroid phase. Women already taking NDT should have TSH checked at 6 to 8 weeks postpartum, since thyroid requirements often drop after delivery and over-replacement in the postpartum period carries its own risks.

Perimenopause: The Diagnostic Minefield

Perimenopause and hypothyroidism share an embarrassing number of symptoms: fatigue, weight gain, brain fog, mood changes, sleep disruption, and irregular periods. A 2021 review in Menopause noted that many women in their late 40s have symptoms labeled as "estrogen deficiency" that have a thyroid component, and vice versa. Women on NDT entering perimenopause should have TSH and free T3 rechecked, because the declining estrogen of perimenopause reduces TBG and may mean an existing NDT dose is now slightly supra-physiologic.

Post-Menopause

Post-menopausal women on oral menopausal hormone therapy (MHT) containing oral estradiol need higher thyroid replacement doses, as noted above. Women on transdermal estradiol-only MHT generally do not. After age 65, the thyroid reference range shifts slightly upward in many laboratory systems, and the cardiovascular risk of over-replacement (atrial fibrillation, bone density loss) becomes more clinically pressing. The T3 peak from NDT may be a larger concern in older post-menopausal women with any pre-existing cardiac history.

Who Is Most Likely to Benefit from Armour Thyroid (and Who Is Not)

Women Who May Benefit

• TSH within reference range on levothyroxine but persistent fatigue, cognitive symptoms, or weight difficulty
• Known or suspected DIO2 polymorphism (Thr92Ala)
• Personal preference after informed discussion of the evidence
• Women who have tolerated levothyroxine poorly due to filler sensitivities (though NDT contains porcine-derived excipients that carry their own allergen considerations)

Women for Whom Levothyroxine Remains the Clearer Choice

• Pregnant women or those actively trying to conceive (more predictable dose titration)
• Women with a history of atrial fibrillation, significant osteoporosis, or cardiac arrhythmia (the T3 spike carries higher risk in these groups)
• Post-menopausal women over 65 with cardiovascular risk factors
• Women with TSH below the lower reference limit on current therapy (already over-replaced)
• Strict vegans or those with religious objections to porcine products

Dosing, Monitoring, and Practical Considerations for Women

Starting Dose and Titration

NDT is typically started at 30 mg (half a grain) daily for women who are currently on levothyroxine, with conversion calculated at approximately 60 mg NDT equivalent to 100 micrograms levothyroxine (though individual conversion varies). A starting dose in a levothyroxine-naive patient is usually 30 mg daily, increased in 15 mg increments every four to six weeks [9].

Lab Monitoring Targets

TSH alone is insufficient for NDT monitoring because the added T3 suppresses TSH more than an equivalent T4 dose would. Free T3 should be measured alongside TSH. Many clinicians aim for:

• TSH: 0.5 to 2.5 mIU/L
• Free T3: mid-to-upper third of the laboratory reference range
• Free T4: low-normal to mid-normal range (since NDT delivers less T4 per unit than levothyroxine)

Timing and Drug Interactions

Take NDT 30 to 60 minutes before eating, with water. Calcium supplements, iron supplements, antacids, and proton pump inhibitors all reduce thyroid hormone absorption and should be taken at least four hours apart from your NDT dose. Coffee taken within 30 minutes of the dose can reduce absorption by up to 36% [10].

Supply Variability: A Real-World Concern

Unlike synthetic levothyroxine, NDT is sourced from porcine glands, and supply can be inconsistent. Shortages occurred in 2020 and 2021, affecting patients mid-treatment. This is a practical consideration in shared decision-making that prescribers using NDT should discuss openly.

Pregnancy and Lactation Safety Summary

Pregnancy: NDT is not formally contraindicated, but levothyroxine is the guideline-preferred option during pregnancy. If you are already stable on NDT and become pregnant, do not stop abruptly. Contact your prescriber immediately. Increase monitoring to every four weeks through 20 weeks. The ACOG recommendation is a TSH target of <2.5 mIU/L in the first trimester and <3.0 mIU/L in the second and third trimesters.

Lactation: Transfer of T4 and T3 into breast milk occurs but is considered clinically insignificant at standard replacement doses. Breastfeeding is not a contraindication to NDT [8].

Contraception: NDT itself is not a teratogen, so there is no mandatory contraception requirement linked to the drug. Women who wish to become pregnant should optimize TSH to <2.5 mIU/L before conception.

What the Evidence Gaps Mean for You

Women have been chronically under-represented in thyroid trials. The Hoang et al. Trial included only 70 participants. No large prospective registry has specifically enrolled women with hypothyroidism across reproductive stages and stratified outcomes by age, hormonal status, or DIO2 genotype. This is not a reason to dismiss NDT, but it is a reason to be explicit with your prescriber about what your treatment goals are, what symptoms you are trying to address beyond TSH normalization, and how you will define success or failure within a defined timeframe.

A reasonable trial of NDT is 12 to 16 weeks with TSH and free T3 monitoring at 6 to 8 weeks and again at the end of the trial period. If symptoms have not improved and TSH is within target, returning to levothyroxine or adding low-dose liothyronine (T3) to levothyroxine is a legitimate next step.